<DOC>
	<DOCNO>NCT02387125</DOCNO>
	<brief_summary>This Phase 1b , open label , multi-center study CMB305 ( sequentially administer LV305 [ dendritic cell-targeting viral vector express NY-ESO-1 gene ] G305 [ NY-ESO-1 recombinant protein plus GLA-SE ] ) patient melanoma , sarcoma , ovarian cancer , non-small cell lung cancer express NY-ESO-1 . CMB305 novel vivo approach design stimulate body 's immune system fight spread growth cancer patient whose tumor express NY-ESO-1 protein . LV305 give prime-boost approach G305 induce synergistic immunotherapeutic response .</brief_summary>
	<brief_title>A Phase 1b Safety Study CMB305 ( Sequentially Administered LV305 G305 ) Patients With Locally Advanced , Relapsed , Metastatic Cancer Expressing NY-ESO-1</brief_title>
	<detailed_description>This study design investigate examine safety immunogenicity combinatorial regimen call CMB305 , intradermal LV305 administer sequentially intramuscular G305 three month . During Part 1 , dose escalation design utilized patient melanoma , NSCLC , ovarian cancer , sarcoma . After completion Part 1 , study expand Part 2 enroll patient NSCLC , ovarian cancer , synovial sarcoma myxoid/round cell liposarcoma .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Locally advanced , relapse , and/or metastatic cancer low minimal tumor burden , may may measureable ( see Appendix A description ) 2 . Tumor histology consistent one following : In Part 1 , Dose Escalation melanoma , NSCLC , ovarian cancer ( include fallopian tube carcinoma ) , sarcoma ( subtype ) . In Part 2 , Patient Expansion NSCLC , ovarian cancer ( include fallopian tube carcinoma ) , sarcoma subtypes , synovial sarcoma myxoid/round cell liposarcoma 3 . Tumor specimen positive NYESO1 expression IHC and/or RTPCR 4 . If ovarian cancer , cancer antigen 125 ( CA125 ) must ≥ 40 U/mL ( unless patient measureable disease follow CA125 ) ; melanoma , LDH must ≤ ULN 5 . Inadequate response , relapse , and/or unacceptable toxicity one prior systemic , surgical , radiation cancer therapy , curative standard therapy option ( except patient NSCLC must experience either inadequate response , relapse , and/or unacceptable toxicity two prior systemic , surgical , radiation cancer therapy ) 6 . ≥ 18 year age 7 . Life expectancy ≥ 6 month per investigator 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 9 . ECG without evidence clinically significant arrhythmia ischemia 10 . If female childbearing potential ( FCBP ) , willing undergo pregnancy test agrees use least one highly effective two effective contraceptive method dose period three month last CMB305 injection 11 . If male sexually active FCBP , must agree use highly effective contraception latex condom dose period three month last CMB305 injection 1 . Investigational therapy within 3 week prior CMB305 dose 2 . Prior administration NYESO1targeting immunotherapeutics 3 . Significant immunosuppression : 1 . Concurrent , recent ( ≤ 4 week ago ) anticipate treatment systemic corticosteroid dose , 2 . Other immunosuppressive medication methotrexate , cyclosporine , azathioprine ( antihistamine , nonsteroidal antiinflammatory drug aspirin permit ) condition common variable hypogammaglobulinemia exposure large field radiotherapy 4 . Cancer therapy , include chemotherapy , radiation , biologics kinase inhibitor , GCSF GMCSF within 3 week prior first schedule CMB305 dose 5 . Psychiatric , medical illness condition opinion PI prevent compliance study procedure ability provide valid informed consent 6 . Significant autoimmune disease exception alopecia , vitiligo , hypothyroidism condition never clinically active transient completely resolve require ongoing therapy 7 . Myocardial infarction within 6 month study initiation , active cardiac ischemia New York Heart Association ( NYHA ) Grade III IV heart failure 8 . Inadequate organ function include : 1 . Marrow : Peripheral blood leukocyte count ( WBC ) &lt; 3000/mm3 , absolute neutrophil count ≤ 1500/mm3 , platelet &lt; 75000/mm3 , hemoglobin &lt; 10 gm/dL 2 . Hepatic : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 2.5 x ULN , total serum bilirubin &gt; 1.5 x ULN ( patient Gilbert 's Disease may include total bilirubin ≤3.0 mg/dL ) 3 . Renal : Creatinine &gt; 1.5x ULN 4 . Other : INR ( prothrombin time ratio ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN 9 . History cancer within 3 year ( except nonmelanoma cutaneous malignancy cervical carcinoma situ ) . 10 . Active tuberculosis recent ( &lt; 2 week ago ) clinically significant infection evidence active hepatitis B , hepatitis C HIV infection 11 . Uveal melanoma 12 . Brain metastasis consider unstable : 1 . Without confirmed stability 60 day patient previously treat prior surgery radiation ; OR 2 . Associated symptom and/or finding ; OR 3 . Requiring corticosteroid anticonvulsant prior 60 day 13 . Pregnant nursing 14 . Known allergy ( y ) component CMB305 , include egg lecithin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>